Cancer Pain Prevalence and its Management

  • Arslan, Deniz (Department of Medical Oncology, Regional Training and Research Hospital) ;
  • Koca, Timur (Regional Training and Research Hospital, Department of Radiation Oncology) ;
  • Akar, Emre (Cerrahpasa Medical Faculty, Istanbul University) ;
  • Tural, Deniz (Faculty Of Medicine, Akdeniz University) ;
  • Ozdogan, Mustafa (Department of Medical Oncology, Medstar Hospital)
  • Published : 2014.11.06


Pain is a public health problem affecting more than half of cancer patients. Despite the success of the protocols currently used, pain cannot still be reduced satisfactorily in the large majority of patients. In order to improve pain management, all healthcare professionals involved with pain should have sufficient knowledge on pain assessment and treatment, and should inform patients to prevent patient-related barriers. In this compilation, the prevalence values and the treatment methods of cancer pain, and the barriers to pain management have been assessed.



  1. Apolone G, Corli O, Caraceni A, et al (2009). Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer, 100, 1566-74.
  2. Bonica JJ(1990) Cancer pain. In: The Management of Pain, 2nd ed, (ed) Bonica JJ, Philadelphia, Lipponcott Williams & Wilkins, 400-60.
  3. Breivik H, Cherny N, Collett F, et al (2009). Cancer-related pain: a pan European survey of prevalence, treatment, and patient attitudes. Ann Oncol, 20, 1420-33.
  4. Budkaew J, Chumworathayi B(2013). Knowledge and Attitudes toward Palliative Terminal Cancer Care among Thai Generalists. Asian Pac J Cancer Prev, 14, 6173-80.
  5. Burton AW, Cleeland CS(2001). Cancer pain: progress since the WHO Guidelines. Pain Pract, 1, 236-42.
  6. Chapman CR, Casey KL, Dubner R, et al (1985). Pain measurement, an overview. Pain, 22, 1-31.
  7. Cleeland CS, Gonin R, Hatfield AK, et al (1994). Pain and its treatment in outpatients with metastatic cancer. N Engl J Med, 330, 592-6.
  8. Costantini M, Ripamonti C, Beccaro M, et al (2009). Prevalence, distress, management and relief of pain during the last three months of cancer patients' life. Results of an Italian mortality follow-back survey. Ann Oncol, 20, 729-35.
  9. Coyle N, Layman-Goldstein M(2007).Pharmacologic management of adult cancer pain. Oncology (Williston Park), 21, 10-22.
  10. Deandrea S, Montanari M, Moja L, et al (2008). Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol,19, 1985-91.
  11. De Leon-Casasola OA(2004). Interventional procedures for cancer pain management: When are they indicated? Cancer Invest, 22, 630-42.
  12. Demir M, Can G, Celek E(2013). Effect of Reiki on Symptom Management in Oncology. Asian Pac J Cancer Prev, 14 (8), 4931-33
  13. Dimopoulos MA, Kastritis E, Bamia C, et al (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol, 20, 117-20.
  14. Foley KM(1985). The treatment of cancer pain. N Engl J Med, 313, 84-94.
  15. Gong X, Wang J, Liu F, et al (2013). Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev, 14, 2937-43.
  16. Grond S, Zech D, Diefenbach C, et al (1996). Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain, 64, 107-14.
  17. Han SH, de Klerk JM, Tan S, et al (2002). The PLACORHeN study: a double-blind, placebo-controlled, randomized radionuclide study with (186) Re-etidronate in hormoneresistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med, 43, 1150-6.
  18. Lee YJ, Hyun MK, Yea Ji Jung YJ, et al (2014). Effectiveness of education interventions for the management of cancer pain: a systematic review. Asian Pac J Cancer Prev, 15, 4787-93
  19. Leondi AH, Souvatzoglou MA, Rapti AS, et al (2004). Palliative treatment of painful disseminated bone metastases with 186Rhenium-HeDP in patients with lung cancer. J Nucl Med, 48, 211-9.
  20. Liang S, Wang T, Wu S, et al (2013). Gender differences associated with pain characteristics and treatment in Taiwanese oncology outpatients. Asian Pac J Cancer Prev 14, 4077-82.
  21. Liang S, Chen K, Tsay S, et al (2013). Relationship Between Belief about Analgesics, Analgesic Adherence and Pain Experience in Taiwanese Cancer Outpatients. Asian Pac J Cancer Prev, 14, 713-6.
  22. Mahigir F, Khanehkeshi A, Karimi A(2012). Psychological treatment for pain among cancer patients by rational-emotive behavior therapy - efficacy in both India and Iran. Asian Pac J Cancer Prev, 13, 4561-5
  23. Maltoni M, Scarpi E, Modonesi C, et al (2005). A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer, 13, 888-94.
  24. Marinangeli F, Ciccozzi A, Leonardis M, et al (2004). Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage, 27, 409-16.
  25. McNicol E, Strassels S, Gouds L, et al (2009). NSAIDs or paracetamol, alone or combined with opioids, for cancer pain (Cochrane Review). Cochrane Database Syst Rev, 1, 5180.
  26. McQuay HJ, Collins S, Carroll D, et al (2008). Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev, 2, 1793.
  27. Mercadante S, Bruera E(2006). Opioid switching: a systematic and critical review. Cancer Treat Rev, 32, 304-315.
  28. Mercadante S, Porzio G, Ferrera P, et al (2006). Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage, 31, 242-7.
  29. Miaskowski C, Zimmer EF, Barrett KM, et al (1997). Differences in patients' and family caregivers' perceptions of the pain experience influence patient and caregiver outcomes. Pain, 72, 217-26.
  30. Mitra R, Jones S(2012). Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Car, 29, 70-9.
  31. Morselli M, Bandieri E, Zanin R, et al (2009). Pain and emotional distress in leukaemia patients at diagnosis. Leuk Res, 34, 67-8.
  32. Oldenmenger WH, Sillevis Smitt PA, van Dooren S, et al (2009). A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer, 45,1370-80.
  33. Quigley C(2005). The role of opioids in cancer pain. BMJ, 331, 825-9.
  34. Ripamonti CI, Bandieri E(2011). Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol, 22, 69-77.
  35. Ripamonti C, Bandieri E(2009). Cancer pain. Crit Rev Oncol Hematol, 70, 145-9.
  36. Ripamonti C, Bareggi C(2010). Pharmacology of opioid analgesia: clinical principles. In: Bruera E, Portenoy RK (eds). Cancer Pain. Assessment and Management, Vol. 11. Cambridge: Cambridge University Press, 195-229.
  37. Ripamonti C, Maniezzo M, Campa T, et al (2009). Decreased occurrence of osteonecrosis of the jaws (ONJs) after implementation of dental preventive measure in solid tumours treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Italy. Ann Oncol, 20, 137-45.
  38. Rodriquez M, Baruttell C, Rull M, et al (1994). Efficasy and tolerance of oral dipryone versus oral morphine for cancer pain. Eur J Cancer, 30, 584-7.
  39. Sciuto R, Festa A, Pasqualoni R, et al (2001). Metastatic bone pain palliation with 89-Sr and 186-Re-HeDP in breast cancer patients. Breast Canc Res Treat, 66, 101-9.
  40. Stockler M, Vardy J, Pillai A, Warr D (2004). Acetominophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol, 22, 3389-94.
  41. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG, et al (2007). Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol, 18, 1437-49.
  42. Ventafridda V, De Conno F, Panerai AE, et al (1990). Nonsteroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Int Med Res, 18, 21-9.
  43. Von Roenn JH, Cleeland CS, Gonin R, et al (1993). Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med, 119, 121-6.
  44. Wog R, Wiffen PJ(2002). Bisphosphonates for relief of pain secondary to bone metastases. Cochrane Syst Rev, 2, 2068.
  45. World Health Organization Cancer pain relief: with guide to opioid availability, 2nd edn. World Health Organization, Geneva Switzerland 1996
  46. World Health Organization. Model List of Essential Drugs (EDL). Geneva: World Health Organization, 2007.

Cited by

  1. Intravenous Flurbiprofen Axetil Enhances Analgesic Effect of Opioids in Patients with Refractory Cancer Pain by Increasing Plasma β-Endorphin vol.15, pp.24, 2015,
  2. Oncology Nurses Knowledge and Attitudes Regarding Cancer Pain Management vol.16, pp.17, 2015,
  3. Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels vol.15, pp.1, 2016,
  4. Nurse Attitude-Related Barriers to Effective Control of Cancer Pain among Iranian Nurses vol.17, pp.4, 2016,
  5. Identifying professionals’ needs in integrating electronic pain monitoring in community palliative care services: An interview study vol.31, pp.7, 2017,
  6. The Effect of Pain Management Training on the Severity of Pain in Patients with Cancer: A Clinical Trial Study vol.In Press, pp.In Press, 2019,